# Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)

> **NCT00140985** · PHASE4 · COMPLETED · sponsor: **Organon and Co** · enrollment: 97 (actual)

## Conditions studied

- Renal Disorder

## Interventions

- **DRUG:** MK0954, losartan potassium/Duration of Treatment: 20 weeks
- **DRUG:** Comparator: amlodipine / Duration of Treatment: 20 weeks

## Key facts

- **NCT ID:** NCT00140985
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2002-01
- **Final completion:** 2002-01
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140985, "Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00140985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*